Clinical Efficacy of Trimetazidine in Stable Angina Pectoris: A Double-blind Placebo-Controlled Study

This study which aims to evaluate the effects of trimetazidine on optimalization of medical therapy in patients with eoronary artery disease and positive exereise test and effort angina in spite of medical therapy !ncluding calcium channel blockers, mononitrates and aeetyl salisitic acid for a least two weeks consist of 2 ı patients. In a randomized fashion, patients received 20 mgr trimetazidine tid or plaeebo tablets for two weeks. The ex istence of coronary artery disease was shown with coronary angiography in evcry paticnts. In ten patients which rcccivcd tri- metazidine (Group I; consists of 9 male, ı female patients, m ean age 5 ı ±8 years) occurence of an gina pectoris in a week fell significantly (3.0±2.ı vs 7.2±3.4, p<0.05) with respect to pre-trimetazidine period. But in the placebo group (Group II; consists of 10 male, 1 female patients, mean age 54±7 years) the difference was not significant (5.5±3.5 angina pectoris occurences in a week vs 7.6±3.ı, p>0.05). In the first group, maximum exercise duration, double product at maximum heart rate and time needed for ı mm ST depression were 7.1±1.8 min vs 9.0±2.5 min (p>0.05), 24962±3459 vs 26180±2630 (p>0.05) and 4.3±1.5 min vs 7.9±3.3 min (p0.05), 246ı5±44ı5 vs 25238±30ı2 (p>0.05) and 4.9±1..9 min vs 5.6±2.2 min (p>0.05). These results imply that trimetazidine could be an effective additive to other antianginal agents.